Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Data Showing siRNAs Can Block Infection in CHO Cells


Alnylam Pharmaceuticals this week reported data showing that siRNAs designed to target a virus known to infect Chinese hamster ovary cells, which are used to produce recombinant proteins and monoclonal antibodies, can inhibit infection and viral replication.

In the work, siRNAs were designed and synthesized toward vesivirus, a virus that can infect CHO cells and cause "adverse effects on product quality and/or potential interruption in biologics manufacturing and product supply," the company said. CHO cells grown in suspension culture were infected with vesivirus and then treated with the siRNAs.

"The siRNA treatment was found to potently block viral replication with an approximate 2-log reduction in vesivirus RNA, as measured by PCR," Alnylam noted, adding that the results provide "key proof of concept for applications of RNAi technologies as an antiviral strategy in biologics manufacturing."

About a year ago, Alnylam announced that it established a new initiative, dubbed Alnylam Biotherapeutics, to use its RNAi know-how to improve biologics manufacturing (GSN 11/9/2009).

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.